[Click eStock] "Quantamatrix Resolves Financial Risks with 36 Billion KRW Capital Raise... Accelerates Global Roadmap"

On December 26, independent research firm ValueFinder analyzed Quantamatrix, stating that the company is expected to resolve its financial risks through a capital raise of 36 billion KRW and accelerate its global roadmap with proven technology and strategic capital.

Founded in 2010, Quantamatrix is a manufacturer of rapid antibiotic susceptibility testing products. The company was listed on the KOSDAQ market in 2020 and has expanded its business scope through its antibiotic susceptibility testing product, dRAST. Currently, more than 50 dRAST devices have been deployed in over 10 countries worldwide, mainly in Europe.

In 2026, Quantamatrix is expected to expand into overseas markets and begin clinical entry in the United States in earnest, targeting submission for FDA 510(k) approval. The global business momentum for dRAST is expected to strengthen next year.

On December 22, Quantamatrix issued perpetual convertible bonds worth 36 billion KRW. The acquirer of these perpetual convertible bonds is PentaStone No.3 New Technology Investment Association, in which the listed company Mico holds a 99% stake. Since these bonds do not include refixing or put options, the financing structure is advantageous for the company. On December 24, Quantamatrix also disclosed a management rights transfer agreement, which includes restrictions on the sale of shares held by the existing largest shareholder. Although perpetual convertible bonds are technically debt instruments, they are effectively recognized as equity. This has enabled the company to resolve the legal capital impairment issue, which had previously been a financial risk.

Lee Chungheon, a researcher at ValueFinder, stated, "The acceleration of the company's global roadmap through this capital raise is noteworthy," and explained, "Last July, the company published a paper in the world-renowned scientific journal Nature, introducing its technology that rapidly identifies the optimal antibiotic for patients."

He added, "The uRAST product is targeting a launch within three years, and this capital raise has significantly increased the likelihood of smooth progress in research and development. Quantamatrix has also attracted attention in the securities market as the first Korean company to receive support from the global partnership CARB-X, which is backed by the US government."

Quantamatrix is reported to have secured more than 50 billion KRW in total funding, including this 36 billion KRW capital raise and over 15 billion KRW in research and development funds from the Korean and US governments. He analyzed, "With financial risks resolved, if the company uses these funds to expand its entry into the global market, a revaluation of its corporate value is expected."